Evergreen Capital Management LLC Has $3.32 Million Holdings in AstraZeneca PLC $AZN

Evergreen Capital Management LLC boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 29.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,319 shares of the company’s stock after buying an additional 9,847 shares during the quarter. Evergreen Capital Management LLC’s holdings in AstraZeneca were worth $3,323,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in AZN. Primecap Management Co. CA raised its stake in shares of AstraZeneca by 1.3% in the 2nd quarter. Primecap Management Co. CA now owns 41,200,091 shares of the company’s stock valued at $2,879,062,000 after acquiring an additional 538,606 shares in the last quarter. Franklin Resources Inc. boosted its position in AstraZeneca by 0.9% during the second quarter. Franklin Resources Inc. now owns 21,298,394 shares of the company’s stock worth $1,488,332,000 after purchasing an additional 196,401 shares during the period. Fisher Asset Management LLC grew its holdings in AstraZeneca by 2.6% during the second quarter. Fisher Asset Management LLC now owns 20,695,979 shares of the company’s stock valued at $1,446,235,000 after purchasing an additional 530,520 shares during the last quarter. Jennison Associates LLC raised its position in shares of AstraZeneca by 15.2% in the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after purchasing an additional 1,605,133 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in shares of AstraZeneca by 2.1% in the second quarter. Ameriprise Financial Inc. now owns 5,046,992 shares of the company’s stock worth $351,734,000 after buying an additional 104,625 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AZN. HSBC reiterated a “buy” rating and issued a $108.00 target price on shares of AstraZeneca in a research note on Wednesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Barclays reissued an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a research note on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $94.39 on Friday. The stock has a market cap of $292.78 billion, a P/E ratio of 31.36, a PEG ratio of 1.56 and a beta of 0.34. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $96.51. The company’s 50-day simple moving average is $91.52 and its 200 day simple moving average is $82.83.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The company had revenue of $15.19 billion for the quarter, compared to analyst estimates of $14.75 billion. During the same period in the prior year, the company posted $2.08 EPS. The company’s revenue was up 12.0% compared to the same quarter last year. As a group, research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.